CN105555271A - 含有聚乙二醇的组合物 - Google Patents

含有聚乙二醇的组合物 Download PDF

Info

Publication number
CN105555271A
CN105555271A CN201480051151.8A CN201480051151A CN105555271A CN 105555271 A CN105555271 A CN 105555271A CN 201480051151 A CN201480051151 A CN 201480051151A CN 105555271 A CN105555271 A CN 105555271A
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
formula
alkyl
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480051151.8A
Other languages
English (en)
Chinese (zh)
Inventor
村井健二
山田和人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN105555271A publication Critical patent/CN105555271A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
CN201480051151.8A 2013-09-20 2014-09-18 含有聚乙二醇的组合物 Pending CN105555271A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-195329 2013-09-20
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
CN105555271A true CN105555271A (zh) 2016-05-04

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480051151.8A Pending CN105555271A (zh) 2013-09-20 2014-09-18 含有聚乙二醇的组合物

Country Status (17)

Country Link
US (1) US20160228420A1 (cg-RX-API-DMAC7.html)
EP (1) EP3047850A4 (cg-RX-API-DMAC7.html)
JP (2) JP5856264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160060656A (cg-RX-API-DMAC7.html)
CN (1) CN105555271A (cg-RX-API-DMAC7.html)
AU (1) AU2014322111A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016006153A2 (cg-RX-API-DMAC7.html)
CA (1) CA2924628A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690621A1 (cg-RX-API-DMAC7.html)
HK (2) HK1220632A1 (cg-RX-API-DMAC7.html)
IL (1) IL244648A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016003566A (cg-RX-API-DMAC7.html)
MY (1) MY163236A (cg-RX-API-DMAC7.html)
PH (1) PH12016500461A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201602020QA (cg-RX-API-DMAC7.html)
TW (1) TW201518291A (cg-RX-API-DMAC7.html)
WO (1) WO2015041294A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677346B (zh) * 2015-03-17 2019-11-21 日商參天製藥股份有限公司 含有多肽之醫藥組成物
HK1246641A1 (zh) 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン (スーチョウ) バイオロジー サイエンス アンド テクノロジー カンパニー,リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1918127A (zh) * 2004-02-17 2007-02-21 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的新型环状化合物
CN102471273A (zh) * 2009-07-17 2012-05-23 参天制药株式会社 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2693888A1 (en) 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
BRPI0819849B8 (pt) * 2007-11-26 2021-05-25 Merial Ltd sistemas de solvente para formulações pour on para combater parasitas
CN105362221A (zh) 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1918127A (zh) * 2004-02-17 2007-02-21 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的新型环状化合物
CN102471273A (zh) * 2009-07-17 2012-05-23 参天制药株式会社 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
何功杨等: "两种不同处方吲哚美辛滴眼液稳定性比较", 《同济医科大学学报》 *

Also Published As

Publication number Publication date
HK1220632A1 (zh) 2017-05-12
PH12016500461A1 (en) 2016-05-16
WO2015041294A1 (ja) 2015-03-26
JP5856264B2 (ja) 2016-02-09
US20160228420A1 (en) 2016-08-11
IL244648A0 (en) 2016-04-21
JP2016094442A (ja) 2016-05-26
MX2016003566A (es) 2016-06-02
SG11201602020QA (en) 2016-04-28
KR20160060656A (ko) 2016-05-30
TW201518291A (zh) 2015-05-16
MY163236A (en) 2017-08-30
EP3047850A4 (en) 2017-05-10
CA2924628A1 (en) 2015-03-26
JP2015083565A (ja) 2015-04-30
AU2014322111A1 (en) 2016-04-07
HK1221407A1 (en) 2017-06-02
EA201690621A1 (ru) 2016-07-29
BR112016006153A2 (pt) 2017-08-01
EP3047850A1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
JP6872322B2 (ja) クエン酸エステルを含有するデポ剤
JP6955604B2 (ja) 徐放性医薬組成物
JP5856264B2 (ja) ポリエチレングリコール含有組成物
DK2968650T3 (en) EYE PHARMACEUTICAL FORMULATIONS FOR THE POSTERIOR EYE SEGMENT
TWI677346B (zh) 含有多肽之醫藥組成物
TW201639568A (zh) 醫藥組成物之安定保存
HK1246167A1 (en) Depot preparation containing citric acid ester
HK1246167B (en) Depot preparation containing citric acid ester

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220632

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20160504

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220632

Country of ref document: HK